Technical Analysis for AEZS - AEterna Zentaris Inc.
|Grade||Last Price||% Change||Price Change|
AEZS closed up 0.99 percent on Friday, October 20, 2017, on 30 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
|Weak or Absent||Down||Up||Down|
|See historical AEZS trend table...|
|Date||Alert Name||Type||% Chg|
|Oct 20||Crossed Above 50 DMA||Bullish||0.00%|
|Oct 20||200 DMA Resistance||Bearish||0.00%|
|Oct 19||Fell Below 50 DMA||Bearish||0.99%|
|Oct 19||Stochastic Reached Oversold||Other||0.99%|
|Oct 18||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup||-0.98%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan. It markets Cetrotide, a luteinizing hormone-releasing hormone antagonist treatment for in vitro fertilization. The company's product pipeline includes AEZS-108, which is in Phase III clinical trial for the treatment of endometrial cancer, as well as in Phase II clinical trial to treat triple-negative breast, ovarian, castration and taxane resistant prostate, and refractory bladder cancers; and AEZS-130, an oral diagnostic test that has completed Phase III clinical trial for adult growth hormone deficiency, as well as in Phase IIA clinical trial for the treatment of cancer-induced cachexia. Its product pipeline also comprise Ozarelix, which is in Phase II clinical trial for the treatment of prostate cancer; Perifosine that is in Phase I/II clinical trials for the treatment of neuroblastoma, glioma, and pediatric solid tumors; and AEZS-112 an oral anticancer agent, which has completed Phase I clinical trial for the treatment of solid tumors and lymphoma. In addition, the company's products in preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate for the treatment of prostate cancer; AEZS-129, 134, and 136 PI3K/Erk inhibitors for oncology; and AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more AEZS news...
|52 Week High||5.08|
|52 Week Low||0.7816|
|200-Day Moving Average||2.0984|
|50-Day Moving Average||2.0168|
|20-Day Moving Average||2.1085|
|10-Day Moving Average||2.125|
|Average True Range||0.1424|
|Chandelier Exit (Long, 3 ATRs )||2.0428|
|Chandelier Exit (Short, 3 ATRs )||2.3472|
|Upper Bollinger Band||2.2642|
|Lower Bollinger Band||1.9528|
|Percent B (%b)||0.25|
|MACD Signal Line||0.0412|
|Market Cap||32.7 Million|
|Num Shares||16.1 Million|
|Price-to-Earnings (P/E) Ratio||-1.19|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||2.20|
|Resistance 3 (R3)||2.20||2.15||2.17|
|Resistance 2 (R2)||2.15||2.11||2.15||2.16|
|Resistance 1 (R1)||2.09||2.08||2.12||2.09||2.15|
|Support 1 (S1)||1.98||2.00||2.01||1.98||1.91|
|Support 2 (S2)||1.93||1.97||1.93||1.90|
|Support 3 (S3)||1.87||1.93||1.89|
|Support 4 (S4)||1.87|